Oncolytic virus and inhibitor for NEDD8-activating enzyme pevonedistat: Promising combination for cancer therapy?

One trendy strategy for oncolytic virus (OV)-mediated cancer immunotherapy is to explore rational combinations to achieve synergistic effects and maximize the therapeutic efficacy. In this issue of Molecular Therapy, Wong et al. 1 Wong B. Bergeron A. Maznyi G. Ng K. Jirovec A. Birdi H.K. Serrano D. Spinelli M. Thomson M. Taha Z. et al. Pevonedistat, a first in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy. Mol. Ther. 2023; (Preprint at) (This Issue)https://doi.org/10.1016/j.ymthe.2023.09.017 Google Scholar have explored a novel combination and demonstrated that pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to increased infection of an oncolytic vesicular stomatitis virus (VSV), promotes tumor cell death, and improves therapeutic outcomes in oncolytic VSV-resistant murine cancer models.